Naltrexone Viatris (Naltrexone Hydrochloride)

Naltrexone, the active ingredient in Naltrexone Viatris, is an opioid antagonist presented as an oral tablet for systemic use. It is employed to help individuals with alcohol dependence and opioid dependence reduce cravings and prevent relapse, acting on the central nervous system to block opioid receptors.

GNH USA supplies Naltrexone Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Naltrexone is an opioid antagonist used in the management of substance dependence disorders.

Alcohol dependence: reduces the urge to drink and supports abstinence in individuals with alcohol use disorder. Opioid dependence: blocks the effects of opioid agonists, helping prevent relapse in patients recovering from opioid addiction. Substance dependence (general): assists in maintaining sobriety across various opioid‑related dependence conditions.

Naltrexone may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Headache - Dizziness - Fatigue

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes or liver injury) - Severe depression or suicidal thoughts - Allergic reactions such as rash, itching, or anaphylaxis

When prescribing Naltrexone, clinicians should consider several safety precautions to minimize risk.

Liver function assessment: evaluate hepatic enzymes before initiating therapy. Depression monitoring: watch for worsening mood or suicidal thoughts. Avoid in acute opioid withdrawal: initiating treatment may precipitate severe withdrawal symptoms. Renal impairment caution: adjust use in patients with significant kidney disease. Hepatic impairment adjustment: dose may need modification in severe liver dysfunction. Store at below 25°C: keep in the original packaging, protect from moisture.

Naltrexone can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Opioid agonists (e.g., morphine, oxycodone): antagonism can precipitate acute withdrawal. - Opioid‑containing cough medicines: may cause loss of analgesia and withdrawal. - Buprenorphine: competitive antagonism may reduce its therapeutic effect.

Moderate Interactions (Monitor Closely): - Antidepressants (especially SSRIs): may increase risk of depression or suicidal ideation. - Hepatotoxic drugs (e.g., isoniazid, methotrexate): combined use may elevate liver injury risk. - CYP2D6 inhibitors (e.g., fluoxetine): may alter naltrexone metabolism, requiring monitoring.